Literature DB >> 19005330

Tuberous sclerosis complex: disease modifiers and treatments.

Kit Sing Au1, Catherine H Ward, Hope Northrup.   

Abstract

PURPOSE OF REVIEW: Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder involving benign growths in multiple organ systems of affected patients. Variable phenotypes from mild to severe have been reported for related as well as unrelated patients affected by TSC. The two causative genes, TSC1 and TSC2, which code for hamartin and tuberin respectively, play central roles in regulating cell survival and proliferation signaling pathways. The severity of disease phenotypes of TSC patients is influenced by the activities of genes both up and down-stream in the associated pathways. RECENT
FINDINGS: The high-expressing12CA repeat variant of the IFNG gene was suggested to contribute lower risk for kidney angiomyolipomas in patients with TSC2 gene mutations. Genetic modifiers for TSC have been localized on chromosomes 3 and 5 of the rat genome. We performed association studies linking the c.68C allele of the 5-hydroxytryptamine receptor 2C gene to lower seizure risk in TSC-affected individuals.
SUMMARY: Genetic and epigenetic factors affecting the activity of each and every interacting partner of the tuberin-hamartin complex could potentially alter the disease presentation. Identifying functional polymorphic variants of interacting partners affecting TSC gene functions will delineate the mechanisms leading to TSC disease severity, ultimately resulting in treatment strategies.

Entities:  

Mesh:

Year:  2008        PMID: 19005330     DOI: 10.1097/MOP.0b013e328318c529

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  8 in total

Review 1.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

2.  A pilot study evaluating genetic alterations that drive tobacco- and betel quid-associated oral cancer in Northeast India.

Authors:  Dhirendra Singh Yadav; Indranil Chattopadhyay; Anand Verma; Thoudam Regina Devi; L C Singh; Jagannath Dev Sharma; Amal Ch Kataki; Sunita Saxena; Sujala Kapur
Journal:  Tumour Biol       Date:  2014-06-19

3.  Evidence for population variation in TSC1 and TSC2 gene expression.

Authors:  Garilyn M Jentarra; Stephen G Rice; Shannon Olfers; David Saffen; Vinodh Narayanan
Journal:  BMC Med Genet       Date:  2011-02-23       Impact factor: 2.103

Review 4.  Mechanism-based treatment in tuberous sclerosis complex.

Authors:  Kristina Jülich; Mustafa Sahin
Journal:  Pediatr Neurol       Date:  2013-12-05       Impact factor: 3.372

5.  Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex.

Authors:  Àlex Rovira; María Luz Ruiz-Falcó; Elena García-Esparza; Eduardo López-Laso; Alfons Macaya; Ignacio Málaga; Élida Vázquez; Josefina Vicente
Journal:  J Neurooncol       Date:  2014-04-27       Impact factor: 4.130

Review 6.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102

7.  A novel TSC2 missense variant associated with a variable phenotype of tuberous sclerosis complex: case report of a Chinese family.

Authors:  Feng Wang; Shiyi Xiong; Lin Wu; Maya Chopra; Xihong Hu; Bingbing Wu
Journal:  BMC Med Genet       Date:  2018-05-30       Impact factor: 2.103

8.  Whole Exome Sequencing in a Series of Patients with a Clinical Diagnosis of Tuberous Sclerosis Not Confirmed by Targeted TSC1/TSC2 Sequencing.

Authors:  Erzsebet Kovesdi; Reka Ripszam; Etelka Postyeni; Emese Beatrix Horvath; Anna Kelemen; Beata Fabos; Viktor Farkas; Kinga Hadzsiev; Katalin Sumegi; Lili Magyari; Pilar Guatibonza Moreno; Peter Bauer; Bela Melegh
Journal:  Genes (Basel)       Date:  2021-09-10       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.